Diagnóstico y Estadificación de Lesión Renal Aguda

Criterios de Diagnóstico

• La lesión renal aguda se define por un aumento de creatinina sérica ≥0,3 mg/dl en 48 horas, o un aumento ≥50% del valor basal en 7 días, o una disminución del volumen urinario a <0,5 ml/kg/h durante 6 horas o más, según los criterios KDIGO 1, 2
• El estadio 1 de lesión renal aguda se caracteriza por un aumento de creatinina ≥0,3 mg/dl en 48 horas o aumento de 50-99% del valor basal en 7 días, según los criterios KDIGO 3, 1
• El estadio 2 de lesión renal aguda se caracteriza por un aumento de creatinina de 100-199% del valor basal en 7 días, según los criterios KDIGO 3, 2
• El estadio 3 de lesión renal aguda se caracteriza por un aumento de creatinina ≥200% del valor basal en 7 días, o creatinina ≥4,0 mg/dl con un aumento agudo de al menos 0,3 mg/dl, o inicio de terapia de reemplazo renal, según los criterios KDIGO 3, 1

Criterios de Volumen Urinario

• El estadio 1 de lesión renal aguda se caracteriza por un volumen urinario <0,5 ml/kg/h durante más de 6 horas, según los criterios KDIGO 3, 2
• El estadio 2 de lesión renal aguda se caracteriza por un volumen urinario <0,5 ml/kg/h durante más de 12 horas, según los criterios KDIGO 3, 2
• El estadio 3 de lesión renal aguda se caracteriza por un volumen urinario <0,3 ml/kg/h durante 24 horas o anuria durante 12 horas, según los criterios KDIGO 3, 2

Interpretación de los Criterios

• La lesión renal aguda se diagnostica cuando se cumple cualquiera de los criterios de creatinina o volumen urinario, según los criterios KDIGO 1, 4
• La estadificación se realiza retrospectivamente cuando el episodio está completo, clasificando según el criterio más grave que se haya cumplido, según los criterios KDIGO 2, 5

Aplicación Clínica

• La detección temprana de lesión renal aguda debe realizarse en tiempo real basándose en cambios iniciales en los marcadores, según los criterios KDIGO 2, 5
• Los pequeños aumentos en la creatinina sérica (≥0,3 mg/dl) se asocian independientemente con un aumento de aproximadamente cuatro veces en la mortalidad hospitalaria, según los criterios KDIGO 1, 2
• La progresión a través de los estadios de lesión renal aguda se correlaciona fuertemente con un aumento de la mortalidad, según los criterios KDIGO 6, 7

Acute Kidney Injury Diagnostic Criteria and Laboratory Findings

Diagnostic Criteria

• The Kidney Disease Improving Global Outcomes (KDIGO) criteria define AKI as an abrupt decrease in kidney function occurring over 7 days or less, characterized by an increase in serum creatinine by ≥0.3 mg/dL within 48 hours, or an increase in serum creatinine to ≥1.5 times baseline within the previous 7 days, or urine volume <0.5 mL/kg/h for 6 consecutive hours, according to the Kidney International guidelines 8

Urinalysis Findings

• Urinalysis can help differentiate the etiology of AKI, with the presence of hematuria (>50 RBCs per high-power field) possibly indicating glomerular disease, and the presence of proteinuria (>500 mg/day) suggesting glomerular disease, as noted by the Clinical Gastroenterology and Hepatology journal 9
• The presence of cellular casts, particularly renal tubular epithelial cell casts, suggests acute tubular necrosis, as reported in the Kidney International journal 10

Factors Affecting Laboratory Interpretation

• Serum creatinine has limitations as a marker of AKI, being affected by muscle mass, age, sex, and nutritional status, and may underestimate severity of renal function reduction in patients with cirrhosis, as discussed in the Kidney International journal 11
• Hyperbilirubinemia can result in inaccurate measurement of serum creatinine by colorimetric methods, as noted in the Clinical Gastroenterology and Hepatology journal 9

Novel Biomarkers

• Several biomarkers, including Neutrophil gelatinase-associated lipocalin (NGAL), Kidney injury molecule-1 (KIM-1), Tissue inhibitor metalloproteinase-2 (TIMP-2), and insulin-like growth factor-binding protein 7 (IGFBP7), are being studied for earlier detection of AKI, as reported in the JAMA network open journal 12

Imaging Findings

• Renal ultrasound is recommended to evaluate kidney size and rule out obstruction, with normal kidney size suggesting AKI rather than chronic kidney disease, as recommended by the Kidney International guidelines 10

Acute Kidney Injury Staging and Diagnostic Criteria

Diagnostic Criteria and Staging

• The Kidney Disease Improving Global Outcomes (KDIGO) criteria define Acute Kidney Injury (AKI) by an increase in serum creatinine to ≥1.5 times baseline within the previous 7 days 13
• Stage 1 AKI is characterized by an increase in serum creatinine 1.5-1.9 times baseline or an increase in serum creatinine by ≥0.3 mg/dL, or urine output <0.5 mL/kg/h for 6-12 hours 13, 14, 15
• Stage 2 AKI is defined by an increase in serum creatinine 2.0-2.9 times baseline or urine output <0.5 mL/kg/h for ≥12 hours 13, 14, 15
• Stage 3 AKI is characterized by an increase in serum creatinine ≥3.0 times baseline, or urine output <0.3 mL/kg/h for ≥24 hours, or anuria for ≥12 hours 13, 14, 15
• The progression of AKI through stages strongly correlates with increased mortality, according to the KDIGO guideline 13, 15
• The KDIGO guideline modified criteria for stage 3 AKI to include rises in creatinine to ≥4.0 mg/dL when the rise is >0.3 mg/dL or >50% within the specified time frames 14

Biomarkers and Special Considerations

• Newer approaches propose combining damage and functional biomarkers with clinical information to improve diagnostic accuracy, as suggested by the JAMA network open 16
• A proposed modification of KDIGO stage 1 AKI includes three substages (1S, 1A, and 1B) based on biomarker presence, according to the JAMA network open 16
• Stage 1S identifies early kidney injury detected by biomarkers but not by creatinine and urine output criteria, as proposed by the JAMA network open 16
• Urine output criteria may be problematic in certain patient populations, such as those with cirrhosis and ascites, who may be oliguric despite relatively normal kidney function, according to the Gut and Journal of Hepatology 13, 15

Acute Kidney Injury Diagnostic Considerations

Limitations of Diagnostic Criteria

• Serum creatinine significantly overestimates actual kidney function in certain populations, including those with muscle wasting, increased tubular secretion of creatinine, volume expansion, or hyperbilirubinemia 17, 18
• In patients with cirrhosis and ascites, urine output criteria are unreliable due to oliguria with avid sodium retention despite maintaining relatively normal GFR, and diuretic treatment further confounds urine output interpretation 17, 19
• For cirrhotic patients, focus primarily on serum creatinine changes rather than urine output, and note that a serum creatinine threshold of ≥1.5 mg/dL predicts AKI progression and worse prognosis in this population 17, 19

Diagnostic Criteria for Acute Kidney Injury in Special Populations

Considerations for Cirrhotic Patients

• In cirrhotic patients with ascites, the Kidney Disease: Improving Global Outcomes (KDIGO) guideline recommends focusing exclusively on serum creatinine changes, as urine output criteria are unreliable due to avid sodium retention and potential diuretic therapy, with a threshold of creatinine ≥1.5 mg/dL predicting AKI progression and worse prognosis 20
• The European Association for the Study of the Liver (EASL) suggests that cirrhotic patients with ascites are frequently oliguric with avid sodium retention yet maintain relatively normal GFR, and diuretic therapy further confounds urine output interpretation 20

Diagnostic Approach

• The American College of Physicians (ACP) recommends not waiting for creatinine to reach 1.5 mg/dL before diagnosing AKI, as this outdated threshold often indicates GFR has already fallen to ~30 mL/min, and instead suggests monitoring temporal changes in creatinine at 48-hour intervals to detect the 0.3 mg/dL threshold 20
• The National Institute for Health and Care Excellence (NICE) advises against relying on urine output alone in patients receiving diuretics or those with cirrhosis and ascites, and recommends using dynamic changes from baseline to diagnose AKI 20

Acute Kidney Injury Diagnosis and Staging

Diagnostic Criteria

• The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines define Acute Kidney Injury (AKI) as an absolute increase in serum creatinine of ≥0.3 mg/dL within 48 hours, or an increase to ≥1.5 times the baseline value within 7 days 21
• The KDIGO criteria can be applied using either the absolute change criterion or the relative change criterion to diagnose AKI, regardless of baseline kidney function 21

Establishing Baseline Creatinine

• The best approach to establish a baseline creatinine value is to use the most recent known creatinine value from the patient's medical record, as recommended by the Nature Reviews Nephrology 22
• When no baseline exists, an estimated baseline can be back-calculated using the MDRD equation assuming a GFR of 75 mL/min/1.73 m², according to the Kidney International 23, 21

Special Considerations

• The Kidney International suggests that serum creatinine is a concentration and can be diluted by massive fluid resuscitation, potentially masking significant GFR reduction 24, 23
• The Kidney International also recommends adjusting creatinine for volume accumulation in cases of significant fluid resuscitation 24

Guideline Recommendations

• The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines recommend monitoring temporal changes in serum creatinine at 48-hour intervals to detect the 0.3 mg/dL threshold 21
• The Nature Reviews Nephrology recommends using the most recent known creatinine value from the patient's medical record to establish a baseline creatinine value 22

Laboratory Assessment for Acute Kidney Injury

Essential Laboratory Tests

• The American College of Radiology recommends ordering serum creatinine, blood urea nitrogen (BUN), complete blood count with differential, urinalysis with microscopy, and urine chemistry as the core laboratory panel to assess for AKI 25
• Serum creatinine is the primary diagnostic marker, with AKI defined as an increase ≥0.3 mg/dL within 48 hours or ≥50% from baseline within 7 days 26
• Blood urea nitrogen (BUN) should be measured alongside creatinine to help differentiate prerenal from intrarenal causes 25
• Complete blood count with differential helps identify underlying causes such as infection, hemolysis, or thrombotic microangiopathy 25
• Serum electrolytes (sodium, potassium, chloride, bicarbonate) are essential to assess for metabolic complications and guide management 27

Calculated Indices for Etiology Determination

• Fractional excretion of sodium (FENa): FENa <1% suggests prerenal AKI; FENa >2% suggests acute tubular necrosis 25
• Fractional excretion of urea (FEUrea) can be used when diuretics confound FENa interpretation 25

Important Caveats

• Use the most recent known creatinine value from the medical record as baseline—this is superior to imputation methods 28, 29
• If no baseline exists, back-calculate using the MDRD equation assuming GFR of 75 mL/min/1.73 m² 28

Emerging Biomarkers

• Neutrophil gelatinase-associated lipocalin (NGAL) can distinguish acute tubular necrosis from hepatorenal syndrome in cirrhotic patients 30
• Kidney injury molecule-1 (KIM-1) may diagnose AKI before creatinine changes occur 30
• TIMP-2 and IGFBP7 combination predicts progression to severe AKI 30

Additional Testing Based on Clinical Context

• Renal ultrasound is appropriate when obstruction is suspected or to assess kidney size 25
• Serum phosphorus and parathyroid hormone are indicated when eGFR <60 mL/min/1.73 m² to assess for CKD complications 27

Acute Kidney Injury Diagnosis and Management

Biomarkers for AKI Diagnosis and Prognostication

• Urinary TIMP-2 × IGFBP7 >0.3 (ng/mL)²/1000 is associated with death or kidney replacement therapy (hazard ratio 2.16) 31, 32

KDIGO Guidelines for Diagnosis and Staging of Acute Kidney Injury

Diagnostic Criteria

• AKI is diagnosed when any one of the following is present:

• Even a modest creatinine increase of ≥ 0.3 mg/dL is associated with an ≈ 4‑fold increase in in‑hospital mortality. 33

Establishing Baseline Creatinine

• Use the most recent serum creatinine measured within the prior 3 months, selecting the value closest to the time of hospital admission. 34
• If no prior measurement exists, admission creatinine serves as the baseline. 34
• Do not back‑calculate baseline creatinine with MDRD equations in patients with cirrhosis, as this approach is excluded from consensus recommendations. 34

Staging of AKI (KDIGO)

*Higher stages are linked to progressively greater mortality risk. 33

Special Considerations for Patients with Cirrhosis and Ascites

• Serum creatinine changes alone should be used to diagnose AKI; urine‑output criteria are unreliable because these patients often remain oliguric despite relatively preserved glomerular filtration. [34][35]
• Volume expansion from ascites can dilute serum creatinine, lowering its concentration independent of true kidney function. [34][35]

Indications for Emergent Nephrology Consultation

• Stage 2 or Stage 3 AKI warrants prompt nephrology involvement. 34

All statements are derived from peer‑reviewed sources and reflect KDIGO recommendations where applicable.

Fluid Retention in Stage 1 AKI Can Mask True Weight Changes

Mechanisms of Masking

• Intravenous fluid resuscitation dilutes serum creatinine, lowering its measured concentration and potentially hiding a substantial reduction in glomerular filtration rate in stage 1 AKI. 36
• When cumulative fluid gain exceeds 5–10 % of baseline body weight, the measured creatinine should be corrected for volume expansion to avoid under‑estimating AKI severity. 36

Specific Patient Populations

• In patients with decompensated cirrhosis, oliguria combined with avid sodium retention can occur despite relatively preserved GFR, leading to liters of fluid accumulation that conceal concurrent muscle or fat loss. 37
• The ICA‑AKI criteria acknowledge that baseline creatinine underestimates true GFR in cirrhosis because of reduced muscle mass; therefore, even a small absolute rise (≥0.3 mg/dL) signals clinically important kidney injury. 37
• Critically ill individuals who receive large‑volume crystalloid resuscitation may develop stage 1 AKI while retaining enough fluid to mask several kilograms of genuine weight loss. 36

Clinical Implications

• A patient who appears weight‑stable or gains weight during stage 1 AKI may actually be losing muscle and fat, with the loss hidden by 2–5 kg (or more) of retained fluid. 36
• Daily weight measurements combined with precise fluid‑balance calculations (intake – output) are essential to estimate true fluid accumulation and avoid misinterpretation of weight trends. 36
• When fluid retention is suspected, alternative nutritional‑status markers such as prealbumin, mid‑arm circumference, or bioimpedance analysis should be employed to differentiate tissue loss from edema. 36

Common Pitfalls

• Weight alone is unreliable for assessing nutritional status in any stage 1 AKI patient receiving intravenous fluids or with underlying liver disease; clinicians must consider hidden fluid overload. [37][36]
• Urine‑output criteria alone are insufficient in patients on diuretics or with cirrhosis, because oliguria may not reflect true GFR loss in these settings. 37

Assessment Strategy

• Adjust creatinine values for cumulative fluid balance when volume expansion exceeds 5–10 % of baseline weight to obtain a more accurate estimate of renal function. 36
• Recognize that accurate weight‑based assessment of tissue mass is only possible after oliguria resolves and a negative fluid balance is achieved. 37

Confounders and Interferences in Serum Creatinine Interpretation for AKI Diagnosis

Patient‑Related Factors That Lower Baseline Creatinine

Laboratory Assay Interferences

Impact of Chronic Kidney Disease on Small Creatinine Changes

Practical Diagnostic Considerations

Acute Kidney Injury: Diagnosis, Staging, and Follow‑Up (KDIGO‑Based)

Diagnosis Criteria

• AKI is diagnosed when any one of the following is present:

  • Serum creatinine increase ≥ 0.3 mg/dL (≥ 26.5 µmol/L) within a 48‑hour window, or
  • Serum creatinine rise to ≥ 1.5 × baseline within the preceding 7 days, or
  • Urine output < 0.5 mL/kg/h sustained for ≥ 6 consecutive hours.
    These thresholds are the core of the KDIGO AKI definition.* 39

• Only one criterion is required for diagnosis; the three parameters are independent. (KDIGO) 40

Establishing Baseline Creatinine

• Use the most recent outpatient serum creatinine measured within the prior 3 months, selecting the value closest to hospital admission. (KDIGO) 41

• If no prior outpatient value exists, the admission creatinine is accepted as the baseline. (KDIGO) 41

• In patients with cirrhosis, do not back‑calculate baseline creatinine using MDRD equations; this method is explicitly excluded for this population. (KDIGO) 41

Staging Severity

• Stage AKI by the most severe criterion met (creatinine or urine output). (KDIGO) 39

These stage definitions follow KDIGO recommendations.* 40

Monitoring and Follow‑Up

• After AKI is diagnosed, serial monitoring of serum creatinine and urine output is required to determine stage and track progression. (KDIGO) 39

• All patients should be re‑evaluated at 3 months post‑AKI to assess for resolution, new‑onset chronic kidney disease, or progression of pre‑existing kidney disease. (KDIGO) 40

• Even patients without prior CKD who experience AKI have an elevated risk of subsequent kidney dysfunction and should be followed according to KDOQI guidelines. (KDOQI) 39